Targeting the pathobiology of neutrophil extracellular traps
Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.
Scientific Approach
Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.
CIT-013 Development
A first human dosing will be done in 2021 as part of a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody is being carried out by Citryll’s CMC partner Lonza and CTA enabling studies are being finalised in 2020.
Latest News
Press release: Citryll Appoints CTO and CSO
Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.
Press release: Citryll Appoints Chief Medical Officer
Citryll today announced it has appointed Patrick
Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical
development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management / Biometrics, and Drug Safety.
Latest News
Press release: Citryll Appoints CTO and CSO
Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.
Press release: Citryll Appoints Chief Medical Officer
Citryll today announced it has appointed Patrick
Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical
development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management / Biometrics, and Drug Safety.
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…